PT1248618E - Formas polimorficas, amorfas e hidratadas de 5-cloro-3-(4-metanossulfonilfenil)-6'-metil-[2,3']bipiridinilo - Google Patents

Formas polimorficas, amorfas e hidratadas de 5-cloro-3-(4-metanossulfonilfenil)-6'-metil-[2,3']bipiridinilo

Info

Publication number
PT1248618E
PT1248618E PT00980817T PT00980817T PT1248618E PT 1248618 E PT1248618 E PT 1248618E PT 00980817 T PT00980817 T PT 00980817T PT 00980817 T PT00980817 T PT 00980817T PT 1248618 E PT1248618 E PT 1248618E
Authority
PT
Portugal
Prior art keywords
polymorphic
methanosulphonylphenyl
amorfas
bipyridinyl
hydrate
Prior art date
Application number
PT00980817T
Other languages
English (en)
Portuguese (pt)
Inventor
Clas Sophie Dorothee
O'shea Paul
Dalton Chad
Louis S Crocker
James A Mccauley
Richard D Tillyer
Ian W Davies
Original Assignee
Merck Frosst Canada Inc
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc, Merck & Co Inc filed Critical Merck Frosst Canada Inc
Publication of PT1248618E publication Critical patent/PT1248618E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
PT00980817T 1999-11-29 2000-11-27 Formas polimorficas, amorfas e hidratadas de 5-cloro-3-(4-metanossulfonilfenil)-6'-metil-[2,3']bipiridinilo PT1248618E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16792299P 1999-11-29 1999-11-29

Publications (1)

Publication Number Publication Date
PT1248618E true PT1248618E (pt) 2006-07-31

Family

ID=22609368

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00980817T PT1248618E (pt) 1999-11-29 2000-11-27 Formas polimorficas, amorfas e hidratadas de 5-cloro-3-(4-metanossulfonilfenil)-6'-metil-[2,3']bipiridinilo

Country Status (11)

Country Link
US (3) US6441002B1 (https=)
EP (1) EP1248618B1 (https=)
JP (1) JP4425514B2 (https=)
AT (1) ATE320809T1 (https=)
AU (1) AU776544B2 (https=)
CA (1) CA2391650C (https=)
DE (1) DE60026877T2 (https=)
DK (1) DK1248618T3 (https=)
ES (1) ES2259295T3 (https=)
PT (1) PT1248618E (https=)
WO (1) WO2001037833A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521642B2 (en) 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
WO2005085199A1 (en) * 2004-01-14 2005-09-15 Cadila Healthcare Limited Novel polymorphs of etoricoxib
PL2479166T3 (pl) 2009-02-27 2014-11-28 Cadila Healthcare Ltd Sposób otrzymywania etorykoksybu
EA023286B1 (ru) * 2011-05-27 2016-05-31 ФАРМА ДжРС, Д.О.О. Способ получения полиморфной формы i эторикоксиба
EP2773618A1 (en) 2011-11-03 2014-09-10 Cadila Healthcare Limited An improved process for the preparation of etoricoxib and polymorphs thereof
WO2013075732A1 (en) 2011-11-21 2013-05-30 Synthon Bv Process for making crystalline form i of etoricoxib
EP2601952A1 (en) 2011-12-07 2013-06-12 Zentiva, k.s. Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses
WO2013144977A2 (en) * 2012-03-30 2013-10-03 Mylan Laboratories Ltd. An improved process for the preparation of etoricoxib
EP2888231B1 (en) 2012-08-27 2019-01-09 Glenmark Pharmaceuticals Limited Process for preparation of crystalline etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
CN107056691B (zh) * 2017-06-21 2020-03-10 四川尚锐生物医药有限公司 一种制备依托考昔晶型v的方法
WO2019130049A1 (en) 2017-12-29 2019-07-04 Grünenthal GmbH Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain
CN111410629A (zh) * 2020-03-31 2020-07-14 天津大学 依托考昔溶剂化物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321033A (en) 1991-11-15 1994-06-14 Merck Frosst Canada, Inc. Amorphous (quinolin-2-ylmethoxy)indole compounds useful for treating inflammatory diseases
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
IL127441A (en) 1996-07-18 2003-02-12 Merck Frosst Canada Inc Substituted pyridines, pharmaceutical compositions comprising them and their use in the preparation of anti-inflammatory medicaments or as selective cyclooxygenase-2 inhibitors
US6130334A (en) 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6127545A (en) 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6040450A (en) 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
RS49945B (sr) * 1998-04-24 2008-09-29 Merck & Co.Inc., Postupak za sintetizovanje inhibitora cox-2
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis

Also Published As

Publication number Publication date
JP4425514B2 (ja) 2010-03-03
EP1248618A1 (en) 2002-10-16
EP1248618B1 (en) 2006-03-22
JP2003514859A (ja) 2003-04-22
US20020198238A1 (en) 2002-12-26
US6441002B1 (en) 2002-08-27
AU776544B2 (en) 2004-09-16
ATE320809T1 (de) 2006-04-15
DE60026877T2 (de) 2006-11-23
US20030144327A1 (en) 2003-07-31
CA2391650C (en) 2011-01-25
WO2001037833A1 (en) 2001-05-31
ES2259295T3 (es) 2006-10-01
CA2391650A1 (en) 2001-05-31
DK1248618T3 (da) 2006-07-10
DE60026877D1 (de) 2006-05-11
EP1248618A4 (en) 2003-05-14
AU1803101A (en) 2001-06-04

Similar Documents

Publication Publication Date Title
AU2002214505A1 (en) New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
AU2002224927A1 (en) Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
PT1248618E (pt) Formas polimorficas, amorfas e hidratadas de 5-cloro-3-(4-metanossulfonilfenil)-6'-metil-[2,3']bipiridinilo
AU2002362603A1 (en) 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
HUP0300371A3 (en) Tag library compounds, compositions, kits and methods of use
AU2002219322A1 (en) Closed loop fluid-handing system for well drilling
AU2001244399A1 (en) Gamma-secretase inhibitors
AU2002250394A1 (en) Rho-kinase inhibitors
WO2001085978A3 (en) Method for high-throughput lead profiling
AU2001284242A1 (en) Substituted pyrimidines as selective cyclooxygenase-2 inhibitors
AUPQ968300A0 (en) Chemical methods
AU2001251414A1 (en) Method of detecting carcinomas
AU2001290777A1 (en) Intelligent voice bridging
WO2000005214A3 (en) Isoquinolines as urokinase inhibitors
AU2001244646A1 (en) Small drill
NO20010568D0 (no) Substituerte imidazo[1,2a]aziner som selektive inhibitorer for cox-2
IT1319240B1 (it) Procedimento per la oligomerizzazione selettiva dell'etilene.
AU2001255090A1 (en) Cdk inhibitors having 3-hydroxychromen-4-one structure
AU2001294274A1 (en) Antibody inhibiting VPLF activity
AU2001258841A1 (en) Heterocyclic compounds
AU2001283856A1 (en) Bit error rate estimation
AU2001288092A1 (en) Method of crystallization
AU2001293207A1 (en) Nitrogenous heterocyclic compounds
AU2002222644A1 (en) Arylbis (perfluoroalkylsulfonyl) methane, metal salt of the same, and processes for producing these
DZ3356A1 (en) Novel polymorph v of torasemide.